Clotrimazole (Bay b 5097) is a new synthetic antifungal drug with in vitro activity against Candida spp., Torulopsis glabrata, and Saccharomyces spp. Pharmacological studies in man after the oral administration of 1.5 and 3 g of clotrimazole produced mean peak concentrations in the serum of 1.16 and 1.29 mg/ml, respectively, 2 hr after administration. In six patients taking 1.5 g of clotrimazole every 6 hr, there was a progressive decline in the serum concentrations after administration of a dose on days 1, 4, and 8. Nine other patients begun on a similar schedule manifested gastrointestinal symptoms attributed to the clotrimazole and were unable to complete the study. Concentrations of active drug in the urine were less than 1 N of the administered dose.
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Systemic fungal infections contribute significantly to the morbidity and mortality of patients with hematological malignancies (1, 7) and of transplant patients receiving immunosuppressive therapy (13, 17, 20) . Currently, the only antifungal drugs available for the treatment of these infections are amphotercin B and 5-fluorocytosine. The efficacy of amphotercin B is, however, limited by its inherent toxicity (21) . The clinical evaluation of 5-fluorocytosine, though still in progress, appears promising (18, 22) .
Clotrimazole (Bay b 5097, 1 [0 ,chloro-a-a-diphenylbenzyl]imidazole) is a new synthetic antifungal drug developed in Germany (Fig. 1) . Sev- eral reports indicate that this agent has broad in vitro antifungal activity against both pathogenic yeasts and filamentous fungi (10, 12, 16, 23) . The in vivo activity of clotrimazole in experimental fungal infections in animals is variable (12, 15, 23) , and, although clinical activity has been reported (4, 9, 11) phosphatase. There was an interval of at least 48 hr between studies in the same individuals, and all studies were done after an overnight fast. Single-dose studies were performed in seven normal volunteers and one cancer patient with doses of 1.5 and 3 g of clotrimazole. Serum specimens were collected immediately prior to each study and at 1, 2, 3, 4, and 6 hr after administration of the drug. Urine specimens were collected immediately prior to each study and for 6 hr after drug administration.
To determine the effect of multiple dosing on serum levels, 15 cancer patients being treated for their disease in protected-environment units (2) were begun on clotrimazole, 1.5 g every 6 hr for 8 days. All of these patients were receiving prophylactic oral nonabsorbable antibacterial antibiotics (3) were not conducted during courses of cancer chemotherapy. Drug concentrations in serum were determined as described above after the first, the thirteenth (after 72 hr of administration), and the twenty-ninth (after 7 days of administration) doses. Urine specimens were collected for 24 br after the first dose.
Concentrations of clotrimazole in serum and urine were measured by an agar well method with C. pseudotropicalis var. carshalton as the test organism. The organism was inoculated into Sabouraud broth from a fresh agar slant and was incubated for 18 to 24 hr at 37 C. A 50-tuiter sample of the broth culture was inoculated into 50 ml of brain heart infusion agar, which was then distributed in plates. Wells (0.75 mm in diameter by 0.75 mm deep) were cut into the agar and filled with 0.1 ml of the specimens to be measured. The plates were then incubated at 37 C for 18 hr, and the zones of inhibition were measured and compared with a standard curve. The standard curve was prepared by use of a 100 Aig/ml solution of clotrimazole in 95% ethanol. Dilutions of this solution were made with normal human serum to contain 0.5, 1.0, 2.0, and 4.0 pg/ ml. Zones of inhibition were measured after 18 hr of incubation at 37 C. All determinations were performed in triplicate.
The standard error of the mean was calculated by the method of Mantel (8) . The 95% confidence limits were determined as twice the standard error of the mean.
RESULTS
In vitro studies. The antifungal activity of clotrimazole against Candida spp., T. glabrata, and Saccharomyces spp. is shown in Fig. 2 In vivo studies. Figure 3 shows the mean concentrations in the serum of subjects after the oral administration of 1.5 and 3 g of clotrimazole. The mean peak concentration in serum after the 1.5-g dose was 1.16 pig/ml at 2 hr. The mean concentration in serum at 6 hr was 0.24 pg/ml. The range of peak concentrations was from 0.15 to 2.5 pAg/ml and occurred from 1 to 4 hr after the 1.5-g dose.
After the 3-g dose of clotrimazole, the mean peak concentration in serum was 1 was 0.78 ,ug/ml. At this dosage, the range of peak concentrations was 0.49 to 3.5 ,ug/ml and occurred from 2 to 6 hr after administration.
Only 6 of the 15 patients who were begun on a dosage regimen of 1.5 g of clotrimazole every 6 hr could tolerate the drug for the 8 days of study. The other nine patients were unable to continue owing to various degrees of nausea, vomiting, abdominal pain, and diarrhea. Figure 4 shows the mean serum concentrations obtained in the six patients who completed the study. Studies were conducted after the first dose on days 1, 4, and 8. After the initial dose, a mean peak concentration of 1.55 ,Ag/ml was observed at 3 hr; this fell to 1.25 ,Ag/ml at 6 hr. On day 4, immediately prior to the first dose, there was a mean serum concentration of 0.43 ,Ag/ml, which rose to a mean peak at 4 hr of 1.03 ,Ag/ml. The mean concentration in serum 6 hr after this dose was 0.83 ,Ag/ml. After 7 days of administration, the mean peak concentration was only 0.65 ,Ag/ml, again at 4 hr after the dose. At 6 hr, the mean serum concentration was 0.27 Ag/lml. Figure 5 illustrates the difference between the serum concentrations obtained after the first dose inthe six patients who tolerated the continuous administration and the nine patients who were unable to continue taking the drug after a variable number of doses. In the former group, a mean peak concentration of 1.55 jAg/ml was observed at 3 hr, compared with a mean peak concentration of 1.08 ,Ag/ml at 4 hr in the latter group. Two of the patients who subsequently became intolerant of the drug had no demonstrable serum activity after the initial 1.5-g dose of clotrimazole. The urinary excretion of clotrimazole after the 1.5-and 3-g doses was extremely low. Less than 1% of the administered dose could be detected as active drug in urine collections for 6 hr after the dose. Similarly, 24-hr collections during the first day of continuous dosing failed to reveal more than 1% of the total dose administered during that time. DISCUSSION In the present study, the in vitro activity of clotrimazole against the three groups of fungi tested was similar to that reported previously. The MIC for the majority of Candida spp. was 1.56 ,g or less/ml, a level that can be achieved in the serum by oral administration of the drug. Somewhat less activity was observed for clotrimazole against T. glabrata and Saccharomyces spp. Although serious infections may be caused by these latter two organisms (14, 19) , disseminated candidiasis constitutes the major threat to patients who are susceptible to systemic fungal infections (1) .
The results of the pharmacology studies are of interest in several respects. In the single-dose studies, the peak concentration in serum occurred from 1 to 6 hr after administration, and there was considerable variability in these peak concentrations, a result which suggests that the absorption of clotrimazole is erratic. In addition, two patients failed to show any serum activity of clotrimazole after a 1.5-g dose.
Clotrimazole was poorly tolerated when given VOL. 2, 1972 in multiple daily doses for several days. (15) . An alternative explanation foi the decreasing serum concentrations after continuous administration is the nausea, attributed to the clotrimazole, which occurred in the majority of patients by the end of the study. The concomitant administration of nonabsorbable antibiotics could also be a contributory factor.
The development of a better-tolerated oral preparation or a suitable parenteral form of clotrimazole will facilitate the therapeutic evaluation of this agent, which clearly possesses significant in vitro activity against a wide range of pathogenic fungi.
